This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AMN Healthcare (AMN) Releases Solid Preliminary Q4 Revenues
by Zacks Equity Research
AMN Healthcare (AMN) posts solid fourth-quarter 2020 revenue data on the back of strong demand for the company's services across its three segments.
Hologic (HOLX) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Hologic's (HOLX) impressive preliminary results for the first quarter of fiscal 2021 and regulatory approvals.
Illumina (ILMN), Helix Partner to Develop Tracking Setup in U.S.
by Zacks Equity Research
Illumina (ILMN) collaborates with Helix with support from the CDC to set up an enhanced surveillance infrastructure to track the emergence and prevalence of B.1.1.7.
National Vision (EYE) Rides on Comps Growth Amid COVID-19 Woes
by Zacks Equity Research
National Vision's (EYE) Eyeglass pumps sales are robust driven by increases in both customer transactions and average ticket.
Hologic (HOLX) Rides on Robust Preliminary Q1 Organic Sales
by Zacks Equity Research
The uptick in Hologic's (HOLX) Diagnostics sales is likely the result of increased demand for COVID-19 testing.
Hologic (HOLX) to Expand in Oncology With Biotheranostics Buyout
by Zacks Equity Research
Hologic (HOLX) aims to strengthen its Diagnostics business by foraying into the oncology adjacency space via the acquisition of Biotheranostics.
Is Patterson Companies (PDCO) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (PDCO) Outperforming Other Medical Stocks This Year?
Cardinal Health (CAH) Unveils New Logistics Management Tool
by Zacks Equity Research
Cardinal Health's (CAH) company, OptiFreight Logistics, launched TotalVue Analytics to help healthcare supply chain leaders to drive cost savings.
DENTSPLY (XRAY) Acquires Byte to Boost Clear Aligner Business
by Zacks Equity Research
DENTSPLY (XRAY) acquires Byte to strengthen presence in the lucrative clear aligner space.
Here's Why You Should Retain Cardinal Health (CAH) Stock Now
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment, diversified product portfolio and buyouts.
Here's Why You Should Retain Integer Holdings (ITGR) Stock Now
by Zacks Equity Research
Integer Holdings (ITGR) continues to gain traction from portfolio management. However, intense competition is a woe.
OPKO Health's (OPK) BioReference Starts Fan Testing Program
by Zacks Equity Research
OPKO Health's (OPK) BioReference commences mandatory, large-scale COVID-19 testing programs for fans for AFC Division Wild Card playoff game.
Patterson Cos. (PDCO) Down 7.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Patterson Cos. (PDCO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Hold on to Cerner (CERN) Stock Now
by Zacks Equity Research
Cerner (CERN) continues to gain from solid prospects in EHR and strategic deals. However, intense competition remains a woe.
Here's Why You Should Hold on to Intuitive Surgical (ISRG) Now
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to gain traction from improving adoption of da Vinci Surgical System. But weak operational performance is a woe.
Nevro's (NVRO) FDA Submission to Treat Patients With PDN
by Zacks Equity Research
Nevro's (NVRO) submission of a pre-market approval supplement to the FDA to seek approval for its Senza System can help in the treatment of chronic pain associated with PDN.
HMS Holdings (HMSY) to be Acquired by Gainwell for $3.4B
by Zacks Equity Research
HMS Holdings (HMSY) entered into an agreement to be acquired by Gainwell in an all-cash transaction deal worth about $3.4 billion.
Here's Why You Should Retain Cooper Companies (COO) Stock
by Zacks Equity Research
Cooper Companies (COO) continues to benefit from solid CVI and CSI product portfolios.
Intersect ENT (XENT) Banks on SINUVA Sales Amid COVID-19 Woes
by Zacks Equity Research
Intersect ENT's (XENT) potential in chronic sinusitis market and progress in SINUVA and PROPEL product lines are encouraging.
Masimo's (MASI) Telehealth Solution Helps in COVID-19 Crisis
by Zacks Equity Research
Masimo (MASI) is lending support to Renown Health through Masimo SafetyNet in order to manage the COVID-19 surge.
Here's Why You Should Retain AmerisourceBergen (ABC) Now
by Zacks Equity Research
AmerisourceBergen (ABC) continues to gain traction from robust pharmaceutical segment and new product launches.
Abiomed's (ABMD) ECMO Technology Completes Successful Treatment
by Zacks Equity Research
Abiomed (ABMD) successfully treats first two patients in the world with the help of its Breethe OXY-1 System.
Here's Why You Should Retain Stryker Stock Right Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in its robotic-arm assisted surgery platform - Mako and broad product portfolio. However, pricing pressure raises concern.
NextGen (NXGN) Solutions Support COVID-19 Vaccine Distribution
by Zacks Equity Research
NextGen (NXGN) lends a hand to the nationwide rollout of COVID-19 vaccines through its robust EHR platform and integrated solutions.
Grab 3 Dental Stocks More Than Doubling Industry Gains for 2021
by Trina Mukherjee
Buy these three top dental stocks that have shown sharp recovery despite market volatility due to the pandemic, and have the potential to continue their bull run in 2021.